MIRM Mirum Pharmaceuticals Inc

Price (delayed)

$92.53

Market cap

$5.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.61

Enterprise value

$5.64B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 13

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, ...

Highlights
The company's gross profit has surged by 59% YoY and by 10% QoQ
The revenue has soared by 50% YoY and by 9% from the previous quarter
Mirum Pharmaceuticals's equity has decreased by 23% from the previous quarter but it has increased by 4% YoY
The quick ratio has declined by 35% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of MIRM

MIRM stock price

How has the Mirum Pharmaceuticals stock price performed over time
Intraday
0.76%
1 week
-7.1%
1 month
-12.53%
1 year
107.42%
YTD
17.14%
QTD
0.16%

Financial performance

How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$569.61M
Gross profit
$463.58M
Operating income
-$796.42M
Net income
-$798.84M
Gross margin
81.4%
Net margin
-140.2%
The company's gross profit has surged by 59% YoY and by 10% QoQ
The revenue has soared by 50% YoY and by 9% from the previous quarter
The gross margin is up by 6% year-on-year

Price vs fundamentals

How does MIRM's price correlate with its fundamentals

Growth

What is Mirum Pharmaceuticals's growth rate over time

Valuation

What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
23.02
P/S
9.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.9
MIRM's price to book (P/B) is 172% higher than its 5-year quarterly average of 8.4 and 57% higher than its last 4 quarters average of 14.6
Mirum Pharmaceuticals's equity has decreased by 23% from the previous quarter but it has increased by 4% YoY
The revenue has soared by 50% YoY and by 9% from the previous quarter
MIRM's price to sales (P/S) is 28% lower than its 5-year quarterly average of 13.2 but 23% higher than its last 4 quarters average of 7.7

Efficiency

How efficient is Mirum Pharmaceuticals business performance

Dividends

What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIRM.

Financial health

How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 37% higher than its total liabilities
The total liabilities has grown by 42% YoY and by 23% from the previous quarter
The company's current ratio fell by 35% YoY and by 22% QoQ
The company's debt is 33% higher than its equity
The debt to equity has grown by 32% from the previous quarter
Mirum Pharmaceuticals's equity has decreased by 23% from the previous quarter but it has increased by 4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.